Autologous stem cell transplantation (ASCT) has been the mainstay of multiple myeloma (MM) treatment for approximately 30 years. Although the continuous introduction of novel agents in the armamentarium against MM has questioned its value, ASCT remains a backbone treatment for fit MM patients. However, there is no unanimous approach for several aspects including the positioning of ASCT in the therapeutic algorithm either upfront or following the first relapse, the need for single or tandem ASCT, as well as the role of ASCT as salvage therapy. Furthermore, the anti-CD38 monoclonal antibodies along with the next generation proteasome inhibitors and immunomodulatory drugs provide a platform for optimizing the induction and consolidation/maintenance regimens. In this review, we present current data pertaining to all aspects of ASCT in MM, whereas we highlight the open issues that should be addressed in the design of future clinical trials in the field.

中文翻译：

---

多发性骨髓瘤：自体移植的作用。

自体干细胞移植（ASCT）一直是多发性骨髓瘤（MM）治疗的主要手段，已有近30年的历史。尽管在针对MM的军备库中不断引入新型药物质疑其价值，但ASCT仍然是适合MM患者的主要治疗手段。但是，在几个方面都没有一致的方法，包括在治疗算法中将ASCT定位在治疗的前期或第一次复发后，单次或串联ASCT的需要以及ASCT作为抢救疗法的作用。此外，抗CD38单克隆抗体以及下一代蛋白酶体抑制剂和免疫调节药物为优化诱导和巩固/维持方案提供了平台。在这篇评论中，我们介绍了与MM中ASCT各个方面有关的最新数据，